A Liquid Chromatography High-Resolution Tandem Mass Spectrometry Method to Quantify QS-21 Adjuvant and Its Degradation Products in Liposomal Drug Formulations

Identification and quantification of an active adjuvant and its degradation product/s in drug formulations are important to ensure drug product safety and efficacy. QS-21 is a potent adjuvant that is currently involved in several clinical vaccine trials and a constituent of licensed vaccines against malaria and shingles. In an aqueous milieu, QS-21 undergoes pH- and temperature-dependent hydrolytic degradation to form a QS-21 HP derivative that may occur during manufacturing and/or long-term storage. Intact QS-21 and deacylated QS-21 HP elicit different immune response profiles; thus, it is imperative to monitor QS-21 degradation in vaccine adjuvant formulation. To date, a suitable quantitative analytical method for QS-21 and its degradation product in drug formulations is not available in the literature. In view of this, a new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and qualified to accurately quantify the active adjuvant QS-21 and its degradation product (QS-21 HP) in liposomal drug formulations. The method was qualified according to the FDA Guidance for Industry: Q2(R1). Study results showed that the described method presents good specificity for QS-21 and QS-21 HP detection in a liposomal matrix, good sensitivity characterized by the limit of detection (LOD)/limit of quantitation (LOQ) in the nanomolar range, linear regressions with correlation coefficients, R2 > 0.999, recoveries in the range of 80–120%, and precise detection and quantification with % relative standard deviation (RSD) < 6% for QS-21 and < 9% for the QS-21 HP impurity assay. The described method was successfully used to accurately evaluate in-process and product release samples of the Army Liposome Formulation containing QS-21 (ALFQ).

[1]  N. Waters,et al.  First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults. , 2022, Vaccine.

[2]  J. Anguita,et al.  Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants , 2022, Frontiers in Immunology.

[3]  C. Fontana,et al.  Structure Elucidation of Triterpenoid Saponins Found in an Immunoadjuvant Preparation of Quillaja brasiliensis Using Mass Spectrometry and 1H and 13C NMR Spectroscopy , 2022, Molecules.

[4]  J. Anguita,et al.  Replacing the Rhamnose‐Xylose Moiety of QS‐21 with Simpler Terminal Disaccharide Units Attenuates Adjuvant Activity in Truncated Saponin Variants , 2020, Chemistry.

[5]  C. Fox,et al.  A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield. , 2020, Journal of chromatography. A.

[6]  C. Alving,et al.  Liposome Formulations as Adjuvants for Vaccines. , 2020, Current topics in microbiology and immunology.

[7]  Z. Beck,et al.  Army Liposome Formulation (ALF) family of vaccine adjuvants , 2020, Expert review of vaccines.

[8]  A. Poveda,et al.  Exploiting structure-activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants. , 2019, Chemical communications.

[9]  M. Lacaille‐Dubois.  Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review☆ , 2019, Phytomedicine.

[10]  D. Marciani.  Elucidating the Mechanisms of Action of Saponin-Derived Adjuvants. , 2018, Trends in pharmacological sciences.

[11]  E. Jongert,et al.  Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine , 2017, Human vaccines & immunotherapeutics.

[12]  R. A. van den Berg,et al.  Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity , 2017 .

[13]  Alberto Fernández-Tejada,et al.  Design, synthesis and evaluation of optimized saponin variants derived from the vaccine adjuvant QS-21 , 2017 .

[14]  N. Waters,et al.  Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. , 2017, Vaccine.

[15]  F. Wallace,et al.  Analysis of an immunoadjuvant saponin fraction from Quillaja brasiliensis leaves by electrospray ionization ion trap multiple-stage mass spectrometry , 2017 .

[16]  A. Didierlaurent,et al.  Adjuvant system AS01: helping to overcome the challenges of modern vaccines , 2017, Expert review of vaccines.

[17]  N. Garçon,et al.  From discovery to licensure, the Adjuvant System story , 2016, Human vaccines & immunotherapeutics.

[18]  Derek S. Tan,et al.  Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis , 2016, Accounts of chemical research.

[19]  Derek S. Tan,et al.  Quillaja saponin variants with central glycosidic linkage modifications exhibit distinct conformations and adjuvant activities , 2016, Chemical science.

[20]  D. Marciani.  Is fucose the answer to the immunomodulatory paradox of Quillaja saponins? , 2015, International immunopharmacology.

[21]  Z. Beck,et al.  Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. , 2015, Biochimica et biophysica acta.

[22]  D. Marciani.  New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. , 2014, Drug discovery today.

[23]  Derek S. Tan,et al.  Development of a minimal saponin vaccine adjuvant based on QS-21 , 2014, Nature chemistry.

[24]  R. Pons,et al.  Atomic Model and Micelle Dynamics of QS-21 Saponin , 2014, Molecules.

[25]  N. Dendouga,et al.  Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. , 2012, Vaccine.

[26]  P. Livingston,et al.  Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer , 2011, Expert review of vaccines.

[27]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[28]  G. Leroux-Roels,et al.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.

[29]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[30]  E. Maraskovsky,et al.  ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines , 2007, Expert review of vaccines.

[31]  C. Kensil,et al.  QS-21 structure/function studies: effect of acylation on adjuvant activity. , 2002, Vaccine.

[32]  L. Kenne,et al.  Separation and structural analysis of saponins in a bark extract from Quillaja saponaria Molina. , 1999, Carbohydrate research.

[33]  W. Fairbrother,et al.  Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. , 1996, Carbohydrate research.

[34]  C. Kensil,et al.  Adjuvant Activity of QS‐21 Isomers , 1993, Annals of the New York Academy of Sciences.

[35]  C. Kensil,et al.  Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.

[36]  C. Fox,et al.  Vaccine Adjuvants , 2017, Methods in Molecular Biology.

[37]  N. Jacobsen,et al.  Isomerization and formulation stability of the vaccine adjuvant QS-21. , 1996, Journal of pharmaceutical sciences.

[38]  R. Jensen,et al.  [RESEARCH ON SAPONIN, AN ADJUVANT SUBSTANCE WHICH STIMULATES IMMUNITY. I]. , 1964, Revue d'immunologie et de therapie antimicrobienne.